Data suggest photodynamic therapy with the investigational topical methyl aminolevulinate may be an effective treatment for patients with severe facial acne.
The acne app offers a free and immediate analysis of acne type and severity; develops an individualized acne control plan; and monitors users’ progress. It aims to help consumers diagnose, treat, manage and prevent acne.
UK-based Ziarco Pharma Ltd. recently announced positive phase 2a results for ZPL-389, a once daily oral histamine H4 receptor antagonist, for the treatment of moderate to severe atopic dermatitis.
The systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.
Researchers reveal that patients may have concerns with acne consultations. The authors offer tips to improve acne consults.
Acne presents with certain nuances in darker skin patients. Exacerbating factors, treatment approaches and desired treatment outcomes may differ from lighter skin patients.
Researchers report on survey findings that shed light on why patients find acne consultations ineffective.
Pfizer and Anacor Pharmaceuticals announced in May that the pharmaceutical companies merged with Pfizer acquiring Anacor for about $5.2 billion. Dermatologists say merger is a good move for patients.
The investigational sebum-inhibiting topical DRM01 had positive results in a phase 2b study, which paves the way for phase 3 trials planned for 2017.
GlobalMed has represented medical and aesthetic dermatology brands, including BMT, CoolTouch and Radiancy, since 1996. Omnilux noninvasively treats dermatologic conditions, including acne, fine lines and wrinkles and non-melanoma skin cancer.